Although our observations may not extend to noncancer cell lines, ERAP1 is a pharmacological target in cancer therapy and any effects of its inhibition on cancer cell function may have to be validated and evaluated separately to its effect on the immune responses. This evidence concerns the gene ERAP1 and cancer.